Financial Performance - Revenue for the six months ended September 30, 2021, was HK$842,276,000, a significant increase from HK$19,636,000 in the same period of 2020, representing a growth of approximately 4,287%[21] - Gross profit for the same period was HK$79,565,000, compared to a gross loss of HK$4,329,000 in 2020, indicating a turnaround in profitability[21] - Loss for the period was HK$27,128,000, an improvement from a loss of HK$80,070,000 in the previous year, reflecting a reduction in losses by approximately 66%[21] - Total comprehensive income for the period was (3,507) thousand HKD, compared to (22,282) thousand HKD in the previous year, indicating a significant improvement[25] - Loss attributable to owners of the company was (9,765) thousand HKD, a reduction from (71,197) thousand HKD year-on-year[25] - The company reported a loss of approximately HK$27,128,000 for the six months ended September 30, 2021[38] - The Group's net loss for the six months ended 30 September 2021 was approximately HK$27.1 million, a significant improvement compared to a net loss of approximately HK$80.1 million for the same period in 2020[148] Expenses and Costs - Finance costs increased to HK$61,674,000 from HK$45,466,000, representing a rise of about 36% year-over-year[21] - Selling and distribution expenses were HK$9,854,000, up from HK$4,183,000, indicating increased investment in sales efforts[21] - Administrative and other expenses slightly decreased to HK$30,402,000 from HK$30,937,000, showing cost control measures[21] - The total loss before tax for the group was HK$21,752,000, with finance costs amounting to HK$61,674,000[52] - Employee benefit expenses, including directors' remuneration, totaled HK$14,826,000 in wages and salaries for the six months ended September 30, 2021[87] - The income tax expense for the six months ended 30 September 2021 was approximately HK$5.4 million, compared to an income tax credit of approximately HK$4.8 million for the same period in 2020[148] Assets and Liabilities - Total non-current assets increased to 2,260,521 thousand HKD from 2,107,432 thousand HKD, reflecting a growth of approximately 7.25%[27] - Current assets decreased to 1,247,527 thousand HKD from 1,660,927 thousand HKD, a decline of about 25%[27] - Total current liabilities decreased to 2,549,760 thousand HKD from 2,798,898 thousand HKD, showing a reduction of approximately 8.9%[27] - Net current liabilities stood at (1,302,233) thousand HKD, compared to (1,137,971) thousand HKD in the previous period[30] - Total assets as of September 30, 2021, amounted to HK$3,508,048,000[57] - Total liabilities reached HK$2,558,532,000, with borrowings accounting for HK$940,432,000[57] Cash Flow - Cash flows from operating activities showed a net outflow of HK$46,476,000 for the six months ended September 30, 2021[36] - Cash flows from investing activities resulted in a net outflow of HK$124,831,000 during the same period[36] - Financing activities generated net cash inflows of HK$165,186,000 for the six months ended September 30, 2021[36] - Cash and cash equivalents at the end of the period were HK$120,597,000[36] Market and Business Strategy - The company aims to continue expanding its market presence and enhancing product offerings in the upcoming periods[21] - The Group aims to accelerate the construction and pre-sale of properties under development and completed properties held for sale in the People's Republic of China[41] - The Group plans to explore different financing channels to reduce financial costs and improve the revenue and profitability of its healthcare holiday resort development and operation business[148] - The Group continues to focus on residential and industrial property development as its main business[138] - The long-term outlook for the economy and property market in the PRC remains optimistic despite the pandemic's impact[148] Shareholder Information - Basic and diluted loss per share attributable to owners of the company was 0.72 HKD cents, down from 7.85 HKD cents in the previous year[25] - The weighted average number of ordinary shares in issue during the period was 1,358,000,000, compared to 907,400,000 in 2020[99] - The total number of issued shares of the Company was 1,358,000,000 ordinary shares, each with a par value of HK$0.25[194] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code throughout the six months ended September 30, 2021, except for the separation of the roles of chairman and chief executive officer[198] - Mr. Dai Dong Xing serves as both chairman and an executive director, with no position titled "Chief Executive Officer" currently in place[198] - All directors confirmed compliance with the Model Code for securities transactions throughout the six months ended September 30, 2021[198]
保集健康(01246) - 2022 - 中期财报